{"DataElement":{"publicId":"2624970","version":"1","preferredName":"Antibiotic Endodontic Treatment Administered Type","preferredDefinition":"the type of administered drug used to treat infections caused by bacteria and other microorganisms in dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.","longName":"ANTI_ENDTC_ADMIN_TP","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2624953","version":"1","preferredName":"Antibiotic Endodontic Treatment Administered","preferredDefinition":"information related to administered drug used to treat infections caused by bacteria and other microorganisms in dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.","longName":"ANITBIO_ENDOTX_ADMIN","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2624950","version":"1","preferredName":"Antibiotic","preferredDefinition":"(an-tih-by-AH-tik) A drug used to treat infections caused by bacteria and other microorganisms.","longName":"C258","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D605465-750F-0797-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ONEDATA","dateModified":"2007-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2624951","version":"1","preferredName":"Endodontic Treatment Administered","preferredDefinition":"Dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.:Given.","longName":"C52575:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endodontic Treatment","conceptCode":"C52575","definition":"Dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D605465-7520-0797-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ONEDATA","dateModified":"2007-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D605465-7531-0797-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2624956","version":"1","preferredName":"Antibiotic Endodontic Treatment Administered Type","preferredDefinition":"the type of antiobiotic administered during endodontic treatment (root canal).","longName":"ANTIO_ENDOTX_ADMIN_TP","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Quinolones","valueDescription":"Quinolone Compound","ValueMeaning":{"publicId":"2624958","version":"1","preferredName":"Quinolone Compound","longName":"2624958","preferredDefinition":"The basic structure of quinolone is nalidixic acid that has limited therapeutic value.  However, the development of fluorinated quinolones led to new derivative compounds with broad antibacterial activity.  Both DNA gyrase and topoisomerase IV are targets of quinolones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quinolone Antibiotic","conceptCode":"C795","definition":"The basic structure of quinolone is nalidixic acid that has limited therapeutic value.  However, the development of fluorinated quinolones led to new derivative compounds with broad antibacterial activity.  Both DNA gyrase and topoisomerase IV are targets of quinolones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F3E5-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F3FD-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Penicillin","valueDescription":"Penicillin Antibiotic","ValueMeaning":{"publicId":"2624960","version":"1","preferredName":"Penicillin Antibiotic","longName":"2624960","preferredDefinition":"An antibiotic drug used to treat infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin Antibiotic","conceptCode":"C1500","definition":"Any beta-lactam antibiotic derived from Penicillium fungi with bactericidal activity. Penicillin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F40C-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F424-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Cephalosporin (1st Generation)","valueDescription":"Cephalosporin Antibiotic","ValueMeaning":{"publicId":"2624962","version":"1","preferredName":"Cephalosporin Antibiotic","longName":"2624962","preferredDefinition":"A family of antibiotic drugs that is used to treat a wide variety of bacterial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cephalosporin Antibiotic","conceptCode":"C357","definition":"A synthetic or semi-synthetic beta-lactam antibiotic derived from Acremonium (Cephalosporium) fungi with bactericidal activity. Cephalosporin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F433-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F44B-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Carbapenems","valueDescription":"Beta-Lactam Antibiotic","ValueMeaning":{"publicId":"2624964","version":"1","preferredName":"Beta-Lactam Antibiotic","longName":"2624964","preferredDefinition":"Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins, their analogs and derivatives, such as the penem (or penam) compounds, clavulanic acids, and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Lactam Antibiotic","conceptCode":"C260","definition":"A compound with a four member amide ring (beta-lactam), where one member is the amide nitrogen and another is the carbonyl carbon, with bactericidal activity. Beta-lactam antibiotics act by disrupting the synthesis of the peptidoglycan layer of the bacterial cell wall.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F45A-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F472-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Aminoglycosides","valueDescription":"Aminoglycoside Antibiotic","ValueMeaning":{"publicId":"2624966","version":"1","preferredName":"Aminoglycoside Antibiotic","longName":"2624966","preferredDefinition":"A family of antibiotics that works against many types of bacteria and includes streptomycin, gentamicin, and neomycin. Aminoglycosides are used to treat bacterial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglycoside Antibiotic","conceptCode":"C2363","definition":"Any antibiotic containing amino-modified sugars originally isolated from various Streptomyces and Micromonospora species. Aminoglycoside antibiotics bind to the 16S RNA of the bacterial 30S ribosomal subunit, inhibiting translation and protein synthesis. Aminoglycoside use is associated with ototoxicity, neurotxicity and nephrotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F481-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F499-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Tetracyclines","valueDescription":"Tetracycline Antibiotic","ValueMeaning":{"publicId":"2624968","version":"1","preferredName":"Tetracycline Antibiotic","longName":"2624968","preferredDefinition":"Any of a group of broad spectrum naphthacene antibiotics isolated from various species of Streptomyces or produced semisynthetically. In bacteria, tetracycline antibiotics block binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetracycline Antibiotic","conceptCode":"C1595","definition":"Any of a group of broad spectrum naphthacene antibiotics isolated from various species of Streptomyces or produced semisynthetically. In bacteria, tetracycline antibiotics block binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F4A8-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F4C0-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Erythromycin","valueDescription":"Erythromycin","ValueMeaning":{"publicId":"2576825","version":"1","preferredName":"Erythromycin","longName":"2576825","preferredDefinition":"A bacteriostatic antibiotic substance produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythromycin","conceptCode":"C476","definition":"A broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F926-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F4CC-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Clarithromycin","valueDescription":"Clarithromycin","ValueMeaning":{"publicId":"2577826","version":"1","preferredName":"Clarithromycin","longName":"2577826","preferredDefinition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clarithromycin","conceptCode":"C1054","definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F4D8-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin","ValueMeaning":{"publicId":"2575656","version":"1","preferredName":"Azithromycin","longName":"2575656","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F495-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F4E4-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Clindamycin","valueDescription":"Clindamycin","ValueMeaning":{"publicId":"2575671","version":"1","preferredName":"Clindamycin","longName":"2575671","preferredDefinition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clindamycin","conceptCode":"C377","definition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FB55C-F4F0-122E-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Cephalosporin (2nd Generation)","valueDescription":"Cephalosporin (2nd Generation)","ValueMeaning":{"publicId":"2624971","version":"1","preferredName":"Cephalosporin (2nd Generation)","longName":"2624971","preferredDefinition":"Cephalosporin (2nd Generation)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FC9D1-9712-14AA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FCB52-C77B-1058-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ONEDATA","dateModified":"2007-04-05","deletedIndicator":"No"},{"value":"Cephalosporin (3rd Generation)","valueDescription":"Cephalosporin (3rd Generation)","ValueMeaning":{"publicId":"2624972","version":"1","preferredName":"Cephalosporin (3rd Generation)","longName":"2624972","preferredDefinition":"Cephalosporin (3rd Generation)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FCAE1-9C8A-1054-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D5FCB52-C78D-1058-E044-0003BA3F9857","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ONEDATA","dateModified":"2007-04-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB555-13F5-1074-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812087","version":"1","longName":"Endodontics","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812039","version":"1","longName":"PEARL","context":"NIDCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Class of antibiotic drug","type":"Preferred Question Text","description":"Class of antibiotic drug","url":null,"context":"NIDCR"}],"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2D5FB555-1409-1074-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"ALAIS","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}